Researchers suggest that identifying new treatments for autoimmune diseases requires studying the immune system AND target tissues together.
List view / Grid view
Filter the results
Associate Professor Pandurangan Vijayanand from La Jolla Institute for Immunology discusses his study into the body’s immune response to SARS-CoV-2 and why this can vary.
Dr Diogo Camacho from the Wyss Institute at Harvard discusses new research into using machine learning algorithms to analyse RNA sequences and reveal potential drug targets.
Quantitative reverse transcription PCR (RT-qPCR) involves the detection and quantification of RNA.
Professor Laurence D Hurst explains why understanding the nucleotide mutations in viruses, including SARS-CoV-2, can have significant implications for vaccine design.
The new approach enables researchers to isolate brain cells associated with Parkinson's disease and study their gene expression patterns.
Researchers have discovered new drug compounds that target the SKI complex of SARS-CoV-2, preventing replication.
The SARS-CoV-2 RNA genome structure has been studied by researchers who identified several potential drug targets.
A team has revealed how SARS-CoV-2 infects cells, suggesting that targeting its RNA with drugs would stop the virus replicating.
Using supercomputer stimulations researchers reveal that the structural stability of the Ebola nucleocapsid is depended on the presence of RNA and interactions with charged ions.
Researchers have implicated long non-coding RNAs in tumour progression and suggest they may be potential drug targets for cancers with p53 mutations.
Researchers have shown that an siRNA nanomedicine can target BACE1 in a mouse model of Alzheimer's, restoring cognitive capacity.
Emmanuelle Charpentier and Jennifer Doudna have been given the 2020 Nobel Prize in Chemistry for their discovery and development of CRISPR-Cas9 genome editing.